Looking aheadCV benefits expansion A supplemental new drug application (sNDA) is under review to broaden Rybelsuss indication to include major adverse cardiovascular events risk reduction in type 2 diabetes patients with cardiovascular or kidney disease
Individuals whose pituitary gland is no longer capable of producing adequate growth hormone in response to stimulation
Last updated: 31/10/2025 HOW ITS COMPONENTS WORK: A strong antioxidant and detoxifying preparation consisting of L-glutathione reduced (GSH), N-acetylcysteine, grape extract, D-alpha tocopheryle acetate (Vitamin E) and L-lysine
To view or add a comment, sign in New research in Cardiovascular Diabetology A new open-access study with CTCPR - Center for Translational Cardiology and Pragmatic Randomized Trials and international collaborators explores subclinical cardiac dysfunction in people with type 2 diabetes without overt cardiovascular disease
Similarly, a retrospective cohort trial, published in 2025, which included over 295,000 patients from North America, reported GLP1RA use was associated with about a 70% lower risk of incident dementia vs nonuse (HR = 0.30), significant even after statistical matching and multivariable adjustments [20]
